Alzheimer’s Drug Discovery Foundation – Drug Development Program
Event details
| Date | 05.02.2024 |
| Category | Call for proposal |
The Drug Development call supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.
This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this call.
Specifically, the Drug Development call supports the following stages of discovery:
- Early-stage human clinical trials
- Investigational new drug (IND)–enabling studies
Current target areas of interest include:
- Epigenetics
- Inflammation
- Mitochondria & metabolic function
- Neuroprotection
- Proteostasis
- Synaptic activity and neurotransmitters
- Vascular function
- Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)
- Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process
- Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered
Funding:
Max. $5,000,000 based on stage and scope of research
Duration: Multi-year
Eligibility:
Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits.
How to Apply:
Deadlines for proposal submissions occur three times per year. Applications are reviewed in a two-step process: Letters of Intent (LOIs) are the first step, and should be submitted on the ADDF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Winter Deadlines:
- 05 February 2024 (LOI)
- 08 April 2024 (full proposal, by invitation)
Spring Deadlines:
- 13 May 2024 (LOI)
- 22 July 2024 (full proposal, by invitation)
Autumn Deadlines:
- 30 September 2024 (LOI)
- 09 December 2024 (full proposal, by invitation)
Further information
- More information about the program is available here
- Detailed application instructions are here
- The application portal can be found here
Practical information
- General public
- Free